These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 14682015

  • 21. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
    Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD.
    Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099
    [Abstract] [Full Text] [Related]

  • 22. Clinical evaluation of an oral contraceptive containing Ethinyl-Oestradiol (30 mcg) and Gestoden (75 mcg).
    Ferreri R, Abbaticchio L, Blasi N, Conte R, Ierardi GM, Santamato S, Creanza V, Monterubbianesi M.
    Minerva Ginecol; 1993 Dec; 45(12):609-15. PubMed ID: 8139787
    [Abstract] [Full Text] [Related]

  • 23. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
    Schramm G, Heckes B.
    Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Sivin I, Kluft C.
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [Abstract] [Full Text] [Related]

  • 25. The suppression of ovarian function by the new oral contraceptive--Femodene.
    Stickland J, Tolowinska IY, Anthony F, Dennis KJ.
    Contraception; 1987 May; 35(5):447-56. PubMed ID: 3621941
    [Abstract] [Full Text] [Related]

  • 26. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene.
    Düsterberg B, Ellman H, Müller U, Rowe E, Mühe B.
    Gynecol Endocrinol; 1996 Feb; 10(1):33-9. PubMed ID: 8737190
    [Abstract] [Full Text] [Related]

  • 27. [Escapelle - a method of choice for emergency contraception ].
    Tanchev L.
    Akush Ginekol (Sofiia); 2008 Feb; 47 Suppl 2():24-7. PubMed ID: 19496450
    [No Abstract] [Full Text] [Related]

  • 28. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
    Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, Birkhäuser MH, Aubeny E, Knudsen T, Bastianelli C.
    Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
    [Abstract] [Full Text] [Related]

  • 29. Effects of two different oral contraceptives on total body water: a randomized study.
    Machado RB, Tachotti F, Cavenague G, Maia E.
    Contraception; 2006 Apr; 73(4):344-7. PubMed ID: 16531163
    [Abstract] [Full Text] [Related]

  • 30. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
    Andolsek KM, Burkman RT, Kafrissen ME, Olson W, Osterman J.
    Int J Fertil Menopausal Stud; 1993 Apr; 38 Suppl 3():122-5. PubMed ID: 8260970
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N.
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [Abstract] [Full Text] [Related]

  • 33. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive.
    Westhoff C, Osborne LM, Schafer JE, Morroni C.
    Obstet Gynecol; 2005 Jul; 106(1):89-96. PubMed ID: 15994622
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg).
    Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A.
    Contraception; 2004 Nov; 70(5):365-70. PubMed ID: 15504374
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.